@FierceBiotech: Soon-Shiong's NantKwest is spending more on stock buybacks than R&D. Report | Follow @FierceBiotech
@JohnCFierce: Anacetrapib will be either the best come-from-behind PhIII victory or an awfully expensive new cautionary tale about R&D hubris. Hmmmm. | Follow @JohnCFierce
@DamianFierce: Tough day at the Robert J. Coury Global Center, on 1000 Mylan Blvd. More from the WSJ | Follow @DamianFierce
> Political pressure on drug pricing is unlikely to burst the biotech bubble, according to Orbimed Advisors' Sven Borho, saying the odds of policy changes in the U.S. are "extremely remote." More
> France's Enterome Bioscience signed a deal with cancer center Gustave Roussy to explore how microbiomics can play a role in oncology. News
> Roche ($RHHBY) is shutting down four manufacturing facilities as it moves toward specialty medicines. Story
Medical Device News
@FierceMedDev: Resurgent 23andMe CEO says the genetic testing company is not up for sale. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Boston Sci's Watchman hit by restrictive CMS coverage decision, recall over blood leakage. Story | Follow @VarunSaxena2
@EmilyWFierce: Women are suing Endo Health Solutions and Patheon for child support after contraceptive packaging mishap. FiercePharmaManufacturing story | Follow @EmilyWFierce
> Startup gets $14.3M from U.S. military to eliminate imaging in large vessel trauma procedure. Story
> GE Healthcare partners with an Oregon university for cardiovascular research. News
> Medical marijuana startup develops Keurig-like vaporizer device. Article
Pharma News
@FiercePharma: Aratana unveils branding and partnering plans at investor day. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI: Roche whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Article | Follow @EricPFierce
@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. FiercePharmaMarketing report | Follow @CarlyHFierce
> Regeneron expanding New York campus again, adding 300 jobs. More
> Gilead scores additional indications for Harvoni in hep C, HIV patients. Story
> Analysts improve outlook for Teva's Copaxone as it shakes off Novartis competition. Article